Medizinische Universität Graz - Research portal
Marschitz Ingrid Christine |
** = Publications listed in SCI/SSCI/Pubmed
2015
Abstract (Journal)
** Rodl, S; Hubmann, H; Hofer, N; Ulreich, R; Marschitz, I; Cimenti, C; Grangl, G; Zobel, G
LONGTERM EXPERIENCE OF AUTOMATIC REGIONAL CITRATE ANTICOAGULATION IN PEDIATRIC PATIENTS IN RENAL REPLACEMENT THERAPY
PEDIATR NEPHROL. 2015; 30(12):2245-2245.-8th International Conference On Paediatric Continuous Renal Replacement Therapy ; JUL 16-18, 2015; London, UNITED KINGDOM.
[Poster]
Web of Science
** Rodl, S; Hubmann, H; Ulreich, R; Marschitz, I; Hofer, N; Cimenti, C; Grangl, G; Zobel, G
IRON REMOVAL IN TRANSFUSION-ASSOCIATED IRON OVERLOAD WITH DEFEROXAMINE AND RENAL REPLACEMENT THERAPY (HDF) IN A PATIENT WITH END-STAGE RENAL DISEASE (ESRD)
PEDIATR NEPHROL. 2015; 30(12):2244-2244.-8th International Conference On Paediatric Continuous Renal Replacement Therapy ; JUL 16-18, 2015; London, UNITED KINGDOM.
[Poster]
Web of Science
** Rodl, S; Ulreich, R; Cimenti, C; Radauer, W; Marschitz, I; Hofer, N; Grangl, G; Hubmann, H; Zobel, G
INITIAL HIGH VOLUME TREATMENT OF HYPERAMMONAEMIA IN NEONATES WITH PRISMAFLEX HF20 SETS
PEDIATR NEPHROL. 2015; 30(12):2245-2245.-8th International Conference On Paediatric Continuous Renal Replacement Therapy ; JUL 16-18, 2015; London, UNITED KINGDOM.
[Poster]
Web of Science
** Rodl, S; Ulreich, R; Marschitz, I; Hofer, N; Hubmann, H; Cimenti, C; Grangl, G; Zobel, G
TANDEM TREATMENT OF PLASMAPHERESIS AND HEMODIALYSIS WITH CITRATE ANTICOAGULATION IN CHILDREN
PEDIATR NEPHROL. 2015; 30(12):2244-2245.-8th International Conference On Paediatric Continuous Renal Replacement Therapy ; JUL 16-18, 2015; London, UNITED KINGDOM.
[Poster]
Web of Science
2013
Abstract (Journal)
** Rodl, S; Marschitz, I; Mache, CJ; Wendelin, G; Zobel, G;
Long Time Experience of CRRT with the Prismaflex HF 20 Set in Infants and Children.
PEDIAT NEPHROL. 2013; 28(1):183-183.-1st international Symposium on AKI in Children at the 7th International Conference on Pediatric Continuous Renal Replacement therapy; September 27 30, 2012; Cincinnati, Ohio, USA. .
[Poster]
Web of Science
** Rodl, S; Marschitz, I; Mache, CJ; Wendelin, G; Zobel, G;
Outcome of Pediatric Patients with Sepsis and MODS requiring CRRT.
PEDIAT NEPHROL. 2013; 28(1):182-182.-1st international Symposium on AKI in Children at the 7th International Conference on Pediatric Continuous Renal Replacement therapy; September 27 30, 2012; Cincinnati, Ohio, USA.
[Poster]
Web of Science
** Rodl, S; Marschitz, I; Mache, CJ; Wendelin, G; Zobel, G;
Citrate Anticoagulation with the Prismaflex HF 20 Set.
PEDIAT NEPHROL. 2013; 28(1):183-183.-Conference on Pediatric Continuous Renal Replacement therapy;; September 27 30, 2012; Cincinnati, Ohio.
[Poster]
Web of Science
2012
Full paper/article (Journal)
** Rödl, S; Marschitz, I; Mache, CJ; Nagel, B; Koestenberger, M; Zobel, G
Hemodiafiltration in infants with complications during peritoneal dialysis.
Artif Organs. 2012; 36(7): 590-593.
Doi: 10.1111/j.1525-1594.2011.01434.x
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
2011
Full paper/article (Journal)
** Rödl, S; Marschitz, I; Mache, CJ; Koestenberger, M; Madler, G; Rehak, T; Zobel, G
First experience with the Prismaflex HF 20 set in four infants.
Int J Artif Organs. 2011; 34(1): 10-15.
Doi: 10.5301/IJAO.2011.6315
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Rodl, S; Marschitz, I; Mache, CJ; Koestenberger, M; Madler, G; Zobel, G
Continuous Renal Replacement Therapy With Prismaflex HF20 Disposable Set in Children From 4 to 15 kg
ASAIO J. 2011; 57(5): 451-455.
Doi: 10.1097/MAT.0b013e31822d2132
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Rödl, S; Marschitz, I; Mache, CJ; Koestenberger, M; Madler, G; Rehak, T; Zobel, G
One-year safe use of the Prismaflex HF20(®) disposable set in infants in 220 renal replacement treatment sessions.
Intensive Care Med. 2011; 37(5):884-885
Doi: 10.1007/s00134-011-2147-y
Web of Science
PubMed
FullText
FullText_MUG
2010
Abstract (Journal)
** Rodl, S; Marschitz, I; Mache, CJ; Koestenberger, M; Madler, G; Rehak, T; Zobel, G
First Clinical Report of CRRT with the Prismaflex HF 20 Set in an Infant
PEDIAT NEPHROL. 2010; 25(8): 21
[Poster]
Web of Science
** Rodl, S; Marschitz, I; Mache, CJ; Koestenberger, M; Madler, G; Rehak, T; Zobel, G
Initial Clinical Experience with the Prismaflex HF 20 Set in Four Infants
PEDIAT NEPHROL. 2010; 25(8): 20
[Poster]
Web of Science
** Rodl, S; Marschitz, I; Mache, CJ; Koestenberger, M; Madler, G; Rehak, T; Zobel, G
Hemodiafiltration in infants with end-stage renal failure and complications on peritoneal dialyses
PEDIAT NEPHROL. 2010; 25(8): 22
[Poster]
Web of Science
** Rodl, S; Marschitz, I; Mache, CJ; Kostenberger, M; Madler, G; Rehak, T; Zobel, G
First clinical experiences on the renal replacement therapy with the Prismaflex HF 20 Set of four infants and toddlers.
KLIN PADIAT. 2010; 222: S108-S108.
[Poster]
Web of Science
** Rodl, S; Marschitz, I; Rehak, T; Mache, CJ; Kostenberger, M; Madler, G; Zobel, G
Hemodiafiltration in infants with end-stage renal failure and complications of peritoneal dialysis.
KLIN PADIAT. 2010; 222: S14-S14.
[Poster]
Web of Science
** Roedl, S; Rehak, T; Marschitz, I; Zobel, G
Development of Intensive Neuromonitoring of a pediatric Intensive Care Unit in the last 10 Years
KLIN PADIAT. 2010; 222: S53-S53.
[Poster]
Web of Science
** Roedl, S; Rehak, T; Marschitz, I; Zobel, G
12 years experience with extracorporeal therapies in a multidisciplinary pediatric intensive care unit.
KLIN PADIAT. 2010; 222: S108-S108.
[Poster]
Web of Science
2007
Short report/Letter
** Marschitz, I; Rödl, S; Gruber-Sedlmayr, U; Church, A; Giovannoni, G; Zobel, G; Mache, CJ; Raith, J; Plecko, B
Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis.
J Neurol Neurosurg Psychiatry. 2007; 78(1):105-107
Doi: 10.1136/jnnp.2006.090555
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2005
Full paper/article (Journal)
** Schintler, M; Marschitz, I; Trop, M
The use of topical negative pressure in a paediatric patient with extensive burns.
BURNS. 2005; 31(8): 1050-1053.
Doi: 10.1016/j.burns.2005.03.003
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
2003
Full paper/article (Journal)
** Schramek, H; Feifel, E; Marschitz, I; Golochtchapova, N; Gstraunthaler, G; Montesano, R
Loss of active MEK1-ERK1/2 restores epithelial phenotype and morphogenesis in transdifferentiated MDCK cells.
Am J Physiol Cell Physiol. 2003; 285(3): C652-C661.
Doi: 10.1152/ajpcell.00463.2002
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2002
Full paper/article (Journal)
** Schwarzmeier, JD; Shehata, M; Hilgarth, M; Marschitz, I; Louda, N; Hubmann, R; Greil, R
The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.
Leuk Lymphoma. 2002; 43(3):549-554
Doi: 10.1080/10428190290012038
Web of Science
PubMed
FullText
FullText_MUG
Comment
** Anether, G; Marschitz, I; Tinhofer, I; Greil, R
Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Blood. 2002; 99(2):722-723
Doi: 10.1182/blood.V99.2.722
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2001
Full paper/article (Journal)
** Gekle, M; Freudinger, R; Mildenberger, S; Schenk, K; Marschitz, I; Schramek, H
Rapid activation of Na+/H+-exchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2.
Pflugers Arch. 2001; 441(6):781-786
Doi: 10.1007/s004240000507
Web of Science
PubMed
FullText
FullText_MUG
** Holzner, B; Kemmler, G; Sperner-Unterweger, B; Kopp, M; Dünser, M; Margreiter, R; Marschitz, I; Nachbaur, D; Fleischhacker, WW; Greil, R
Quality of life measurement in oncology--a matter of the assessment instrument?
Eur J Cancer. 2001; 37(18):2349-2356
Doi: 10.1016/S0959-8049(01)00307-0
Web of Science
PubMed
FullText
FullText_MUG
2000
Full paper/article (Journal)
** Marschitz, I; Lechner, J; Mosser, I; Dander, M; Montesano, R; Schramek, H
Differential expression of cell-cell adhesion proteins and cyclin D in MEK1-transdifferentiated MDCK cells.
Am J Physiol Cell Physiol. 2000; 279(5):C1472-C1482
Doi: 10.1152/ajpcell.2000.279.5.C1472
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Marschitz, I; Tinhofer, I; Hittmair, A; Egle, A; Kos, M; Greil, R
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.
Am J Clin Pathol. 2000; 113(2):219-229
Doi: 10.1309/491W-L1TN-UFQX-T61B
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Tinhofer, I; Marschitz, I; Henn, T; Egle, A; Greil, R
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
Blood. 2000; 95(2):610-618
Doi: 10.1182/blood.V95.2.610
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Comment
** Tinhofer, I; Wykypiel, H; Marschitz, I; Henn, T; Greil, R
Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway.
Gut. 2000; 46(5):738-740
Doi: 10.1136/gut.46.5.738
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
1998
Full paper/article (Journal)
** Lackner, H; Urban, C; Beham-Schmid, C; Benesch, M; Kerbl, R; Schwinger, W
Treatment of children with anagrelide for thrombocythemia.
J Pediatr Hematol Oncol. 1998; 20(5):469-473
Doi: 10.1097%2F00043426-199809000-00012
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
** Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Blood. 1998; 91(11): 4273-4281.
Doi: 10.1182/blood.V91.11.4273.411k25_4273_4281
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
1997
Full paper/article (Journal)
** Egle, A; Villunger, A; Marschitz, I; Kos, M; Hittmair, A; Lukas, P; Grünewald, K; Greil, R
Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Br J Haematol. 1997; 97(2): 418-428.
Doi: 10.1046/j.1365-2141.1997.382680.x
Web of Science
PubMed
FullText
FullText_MUG
** Villunger, A; Egle, A; Marschitz, I; Kos, M; Böck, G; Ludwig, H; Geley, S; Kofler, R; Greil, R
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Blood. 1997; 90(1): 12-20.
Doi: 10.1182/blood.V90.1.12.12_12_20
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
1996
Comment
** Egle, A; Marschitz, I; Posch, B; Herold, M; Greil, R
IL-10 serum levels in B-cell chronic lymphocytic leukaemia.
Br J Haematol. 1996; 94(1):211-212
Web of Science
PubMed